LoadingLoadingLoadingThe quick read
Latest quote
Net selling: insiders sold $3.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $3.2M and bought $0 of LH stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. $2.4M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Schechter, Adam H (President & CEO), who sold $1.5M. The latest filing was on Aug 18, 2026.
None. No member of Congress disclosed a LH trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (2)
Squarepoint
$35.0M
added
Millennium
$30.6M
added
Sells/Trims (1)
Gotham Asset
$23.2M
trimmed
No tracked top-trader positions in LH right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Financial period
Q2 2026
Earnings per share
$4.79 expected
Revenue
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $4.99 / $4.79Alpha Vantage | +4.18% beat | $3.73B / Unavailable | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $4.25 / $4.12Alpha Vantage | +3.16% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 17, 2026 | $4.07 / $3.94Alpha Vantage | +3.30% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $4.18 / $4.14Alpha Vantage | +0.97% in line | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 24, 2025 | $4.35 / $4.16Alpha Vantage | +4.57% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | $3.84 / $3.73Alpha Vantage | +2.95% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 6, 2025 | $3.45 / $3.39Alpha Vantage | +1.77% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 24, 2024 | $3.50 / $3.49Alpha Vantage | +0.29% in line | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 17, 2026
EPS expected
$4.49 to $4.73
Revenue expected
12 analysts
Last 30 days
Analysts cutting estimates
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.56B | $3.52B | $3.54B | $3.73B |
| Cost of what it sold | $2.54B | $2.60B | $2.60B | $2.62B |
| Gross profit | $1.03B | $920.6M | $938.2M | $1.11B |
| What it spent | ||||
| Sales and admin | $552.4M | $538.6M | $551.0M | $577.2M |
| Other operating costs | $76.1M | — | — | $83.2M |
| Total operating expenses | $628.5M | $538.6M | $551.0M | $660.4M |
| What was left | ||||
| Operating profit | $396.6M | $382.0M | $387.2M | $451.6M |
| Interest on debt | $56.0M | $55.0M | $55.1M | $61.1M |
| Profit before tax | $337.0M | $190.6M | $319.7M | $386.4M |
| Tax | $75.5M | $25.7M | $41.7M | $87.3M |
| Net profit | $261.1M | $164.7M | $277.8M | $298.7M |
| EBITDA | $564.0M | $418.6M | $548.1M | $620.9M |
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
Leans bullishOct 16Piper Sandler raises Opko Health stock price target on LabCorp deal
BullishOct 16OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
NeutralOct 16Opko Health stock hits 52-week high at 1.75 USD
Leans bullishOct 16OPKO Health (NASDAQ:OPK) Stock Rating Raised to Outperform at Barrington Research
Leans bullishOct 16PACS Group, Inc. (PACS) Surges 6.2%: Is This an Indication of Further Gains?
Leans bullishOct 16Labcorp To Pay Up To $872M For BioReference Health Assets, Including 4Kscore Prostate Test
BullishOct 16Labcorp Holdings (LH) Rolls Out Thrive 5 And Posts Solid Results, Is It Fully Priced?
Leans bullishOct 16